Method of treating postoperative corneal erosions following pterygium removal
SUBSTANCE: treating postoperative corneal erosions following pterygium removal. That is ensured by postoperative instillations of drug preparations for corneal erosion. Additionally, the final stage of pterygium removal operation involves administering ozone-oxygen mixture in the concentration of 2 mg/l in an amount of 0.5 ml subconjunctivally. The injection is repeated in the same concentration and amount on the following postoperative day. The method increases the operation effectiveness by reducing postoperative complications and negative symptoms in the patient, including by a compensatory increase of antioxidant enzyme activity, reducing tissue and recovering metabolic processes in the involved tissues, reducing a probability of coarse cicatrisation in the operation region.
EFFECT: method is easy and accessible to implement.
The invention relates to medicine, namely to ophthalmology, and can be used for the treatment of pterygium II-IV degree, including recurrent, with ozone-oxygen mixture.
There is a method of treatment of postoperative corneal erosion after removal of pterygium (G. N. Dushin and other "Surgical treatment of pterygium" / Actual problems of ophthalmology, Moscow, 2009, S. 348-349), which consists in performing installations in the postoperative period after surgery to remove a pterygium drugs for the treatment of postoperative erosion of the cornea.
The disadvantage of this method of treatment is the presence of pain in a long time, on average, 10 days, maybe more depending on the size of pterygium and, accordingly, the area subjected to surgical intervention, expressed corneal syndrome: watery eyes, photophobia, causing blepharospasm in operated patients. In the known method a very long period of epithelization of the cornea and increased recovery time and rehabilitation of the patient in the postoperative period.
The present invention solves the problem of increasing the efficiency of operations by reducing postoperative complications and negative symptoms has been operated on the patient, i.e. in increasing the quality characteristics of the treatment. The technical result consists primarily in a compensatory increase in the activity of antioxidant enzymes superoxide dismutase, catalase and glutathione peroxidase, which explains the antioxidant effect of ozone reduces the degree of tissue hypoxia and restores metabolic processes in diseased tissue at the site of inflammation. In response to the introduction of the ozone-oxygen mixture through the gradual admission of oxygen into the area of inflammation and oxidation algogen-mediators generated at the site of tissue damage that occurs stable anti-inflammatory and analgesic effect. In addition, there is an ozone-oxygen mixture enhances the effects of other drugs that helps in the healing wound surface and shortens the postoperative treatment and rehabilitation of patients. This method reduces the likelihood of rough scarring in the operating area, preventing including degenerative processes in the cornea. The method is simple and available.
This technical result of treatment of postoperative corneal erosion is achieved by the fact that in the treatment of postoperative corneal erosion after removal of the pterygium, which consists in performing post-installation drugs for treatment on reoperations erosion of the cornea, additionally, at the final stage of the operation to remove the pterygium enter subkonyunktivalno ozone-oxygen mixture at a concentration of 2 mg/l in 0.5 ml and repeat the injection of the same concentration and in the same amount the next day after the operation.
Method for the treatment of postoperative corneal erosion after removal of the pterygium is as follows.
At the final stage of the operation to remove the pterygium enter subkonyunktivalno ozone-oxygen mixture at a concentration of 2 mg/l in the amount of 0.5 ml On the next day after surgery, repeat the injection of the same concentration and in the same amount.
Patient P., 1949 birth, outpatient map No. 345521.
DS - pterygium III degrees, when viewed from the medial side of the observed distribution of the pterygoid Maidenhead to the pupillary zone. The patient underwent surgery to remove the pterygium by way Mac Reynolds. At the final stage of the operation to remove the pterygium subkonyunktivalno introduced a solution of ceftazidime 50 mg. In a separate syringe subkonyunktivalno introduced an ozone-oxygen mixture at a concentration of 2 mg/l in the amount of 0.5 ml At day 2 after the operation repeated the injection of the same concentration and in the same amount. Corneal syndrome is absent. Control examination was held in 2 weeks. The eye is at peace, postoperative erosion completely epithelization.
Method for the treatment of postoperative corneal erosion after removal of the pterygium, which consists in performing post-installation drugs for treatment erosion of the cornea, characterized in that additionally at the final stage of the operation to remove the pterygium enter subkonyunktivalno ozone-oxygen mixture at a concentration of 2 mg/l in 0.5 ml and repeat the injection of the same concentration and in the same amount the next day after surgery.
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to a compound presented by formula , or their pharmaceutically acceptable salt, which can find application for treating or preventing ophthalmic diseases.
EFFECT: invention refers to the pharmaceutical compositions and methods of treating the ophthalmic diseases with the use of the above compound.
13 cl, 7 dwg, 7 tbl, 4 ex
SUBSTANCE: method involves corneal impregnation with 0.1% riboflavin and ultraviolet exposure at a wave length of 365-375 nm for 30 min. Before impregnation, the cornea is coated with 40% glucose kept on the corneal surface for 9-11 min; residual glucose is removed, and the glucose-treated corneal surface is coated with 0.1% riboflavin for 30 min.
EFFECT: eliminating postoperative complications, reducing the length of the patients' rehabilitation, and achieving the high functional results of the operation.
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to the pharmaceutical industry and represents an ophthalmic solution containing riboflavin and vitamin E for the UV-A rays protection of the internal structures of an eyeball and for treating keratoconus by transepithelial crosslinking.
EFFECT: invention provides extending the range of products for the UV-A rays protection of the internal structures of the eyeball and for treating keratoconus by transepithelial crosslinking.
9 cl, 10 dwg
SUBSTANCE: simulating this pathology is accompanied by pharmacological preconditioning. That is ensured by using Nicorandil in a single dose of 0.86 mg/kg of body weight which is introduced intragastrically through a probe in the form of a starch solution into a laboratory animal. Ischemia of the retina is simulated 30 minutes later by delivering mechanical pressure of 110 mm Hg on an anterior eye chamber for 30 minutes.
EFFECT: method provides the pronounced correction of ischemic ocular injuries.
1 ex, 1 tbl
SUBSTANCE: method involves simulating retinal pathology and preventing it by administering recombinant erythropoietin as a preconditioning agent into a laboratory animal. Erythropoietin is administered daily once on the first experimental day intragastrically in a dose of 50 IU/kg 30 minutes before simulating the pathology. The method promotes the pronounced correction of ischemia of the retina ensured by a mechanism of opening of ATP-dependent K+-canals followed by inducing mechanisms of metabolic adaptation in implementing the preconditioning effect.
EFFECT: preventing the ischemic conditions of the retina.
1 ex, 1 tbl
SUBSTANCE: invention refers to medicine, namely to ophthalmology and to devices for the intermittent active substance feed into a naso-lachrymal duct. The device comprises a tube inserted into a lachrymal opening plug cavity. The tube comprises hole, which is fluid-connected to a cavity formed in a tube body and comprising a drug. The device also comprises two or more linearly aligned dosage units for the intermittent feed inside the tube; two or more dosage units for the intermittent feed comprises a core containing the active substance, and a water-soluble encapsulating layer surrounding the core. A boundary layer between the first and second dosage unit for the intermittent feed is soluble in lachrymal fluid. A thickness and physical characteristics of the soluble boundary layer can be adjusted to control time intervals between the instants of the intermittent drug feed.
EFFECT: such implementation of the device provides the regulated intermittent feed with the controlled time intervals between the instants of the feed of one or more active substances, including in small amounts, into one or both naso-lachrymal ducts and into the lachrymal fluid through a plug in the lachrymal opening in the form of a linear sequence of feed pulses for delaying or preventing a disorder or a condition of one or more organs, namely eyes, a nose, or a throat.
16 cl, 11 dwg
SUBSTANCE: group of inventions refers to medicine, namely to ophthalmology, and aims at treating eye discomfort. Treating the eye discomfort is ensured by applying a liquid composition containing a cooling agent. The cooling agent represents 2,3-dihydroxypropyl ester of (1R,2S,5R)-2-isopropyl-5-methylcyclohexane carboxylic acid (or CPS-030). The liquid composition of the cooling agent is applied locally on at least a part of the outer surface of the eyelid (preferentially a closed one) to be treated. Preferentially, the liquid composition of the cooling agent is applied on a tissue, a tampon or a wipe or is enclosed into a tissue, a tampon or a wipe, e.g. an eye wipe.
EFFECT: using the group of inventions provides the prolonged relief of the eye discomfort with no eye irritation.
57 cl, 1 tbl, 1 dwg, 6 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to medicine, and concerns an ophthalmic composition for treating dry eye, which is presented in the form of a water-based liquid solution with its base containing rebamipide, meglumine and boric acid, and/or phosphoric acid, wherein the amount of the inorganic cation, different from hydronium ion in the ophthalmic composition is less than 15 mEq.
EFFECT: invention provides maintaining the transparency of the rebamipide-containing solution.
5 cl, 58 ex, 4 tbl
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to compounds of formula
wherein pyridine rings A, B and C are independently unsubstituted or substituted by one or more substitutes independently specified in a group consisting of: C1-6-alkyl, halogen alkyl having 1-6 carbon atoms, Hal or OR13; L1 and L2 are independently specified in residues having formula or , wherein at least one of L1 or L2 has formula (b); R1 and R2 are independently specified in a group consisting of hydrogen, C1-6-alkyl and phenyl; R3 is specified in hydrogen and C1-6-alkyl; R4, R5, R6 and R7 are independently specified in a group consisting of hydrogen and C1-6-alkyl; R8, R9, R10 and R11 are independently specified in a group consisting of hydrogen and C1-6-alkyl; R12 is specified in a group consisting of hydrogen and C1-6-alkyl; R13 is independently specified in a group consisting of hydrogen, C1-6-alkyl and phenyl; p is equal to 1 or 2; q is equal to 0, 1 or 2, and Hal is specified in a group consisting of F, Cl, Br, and I, which can be used in treating a group of amyloid protein related disturbances and disorders.
EFFECT: preparing the compounds which can be used in treating a group of amyloid protein related disturbances and disorders.
17 cl, 1 dwg, 6 tbl, 13 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to the pharmaceutical industry and represents a product in the form of a kit containing the first composition containing a compound specified in azelaic acid or its salts in an amount of approximately 5 wt % to 10 wt % of the total weight of the first composition, and the second composition different from the first one and containing a compound specified in a group consisting of brimonidine or its salts, in an amount of approximately 0.1 wt % to 0.2 wt % of the total weight of the second composition, as a combined product used as a therapeutic agent for treating inflammatory skin diseases, wherein the first and second compositions can be used either simultaneously, separately or at a time delay.
EFFECT: invention provides the more effective treatment of the inflammatory skin diseases than the treatment using each compound separately with the minimum side effect notwithstanding the time of using the above combination.
13 cl, 7 ex
SUBSTANCE: invention refers to medicine, particularly to treating diabetes. That is ensured by the method for transdermal administration of insulin. The method involves placing a flat applicator pre-soaked in an insulin solution in the form of a porous titanium nickelide plate of the thickness of 0.2 to 1 mm on skin. The plate and skin are heated by an infrared light source, while a procedure length is specified within 30 to 120 minutes. A device used for implementing the method comprises a body with a power supply, a heating element and the flat applicator pre-saturated with insulin. The applicator represents the removable porous titanium nickelide plate of the thickness of 0.2 to 1 mm forming one of the body walls. The heating element is represented by the infrared light source in the form of a light-emitting diode set integrated into the body above the plate.
EFFECT: invention provides the more comfortable procedure by eliminating injuring factors, simplifying the power supply configuration, as well as making the applicator process more ordinary, including a possibility to implement the process in everyday life.
2 cl, 1 ex, 3 dwg
SUBSTANCE: invention refers to medical equipment and can be used for decorative and cosmetic tattooing. A tattoo machine comprises a frame and a permanent magnet. The permanent magnet is mounted to polarise a magnetic flow generated by an inductance coil. The frame of the tattoo machine is made of a non-magnetic material and comprises a holed projection. The inductance coils are arranged on both sides from the projection of the frame. The permanent magnet is cylindrical and integrated into the hole of the projection of the frame so that a magnetic axis is perpendicular to axes of the inductance coils.
EFFECT: enlarging the controlled power range of the device, stabilising operation conditions and reducing heating after the long-term continuous use.
2 cl, 2 dwg
SUBSTANCE: there are presented versions of a method for a penetrant delivery involving creating a number of delivery openings. An opening depth makes from approximately 40 to approximately 90 micron. The above delivery openings are characterised by a distribution resultant in a normal distribution curve. There are also presented versions of a method for assessing the effectiveness of the penetrant delivery through a biological membrane, involving measuring the fixed penetrant concentration, measuring a transepidermal water loss through a mammalian membrane and comparing the measurement results to the known values for each providing the desired results.
EFFECT: inventions provide the optimum percutaneous substance delivery to the body by determining the optimum depth range of the delivery openings providing the effective absorption of the therapeutic substances.
25 cl, 10 tbl, 9 dwg, 5 ex
SUBSTANCE: lipoaspiration cannula of the diameter of up to 1.2 mm is used to sample primary aspirate from subcutaneous fat of an anterior abdominal wall. The produced aspirate is washed with 5% glucose to prepare a lipid fraction to be diluted with 5% glucose in ratio 1:1 of glucose-fat, agitated to prepare a suspension. The skin is punctured to insert a blunt-ended injection cannula of the diameter of up to 1.2 mm into soft tissues surrounding an ulcer and immediately under an ulcerous defect. The cannula is delivered to an end of each marked beam, and the prepared suspension is administered at the output by removing the cannula gradually by simultaneous pressing on a syringe piston. Up to 5 insertions of the suspensions are fan-shaped from one puncture herewith creating a perifocal cushion of the thickness of up to 0.7 cm. A distance of passage beams shall not exceed 2-3 mm.
EFFECT: higher quality of treatment of this pathology by forming the normotrophic scar tissue by stimulating regional microcirculation.
3 tbl, 1 dwg, 1 ex
SUBSTANCE: invention refers to medical equipment, namely to drug delivery control units using a magnetic body. The magnetic body comprises a magnet and a coating element attached to an end surface of the magnet. The coating element consists of a material with high magnetic permeability; a length-to-radius ratio of the coating element makes 10:1 to 7:3; the side surface of the coating element is longitudinally tapered, and the upper end of the tapered side surface of the coating element is spherical. The drug delivery control unit comprises the magnetic body, a supporting head for the magnetic body and a head drive mechanism which actuates the head along the projected portion formed by the injured region in relation to the tissues surface.
EFFECT: using the invention enables more effective and adjustable drug delivery.
6 cl, 14 dwg
SUBSTANCE: treating trophic corneal erosion is ensured by processing the corneal erosion structures with ozone-oxygen mixture with the ozone concentration of 1.5 mg/l. The mixture is administered subconjunctivally in a dose of 0.5 ml per one injection. The therapeutic course involves at least 5 procedures and depends of a degree of manifestation of corneal erosion.
EFFECT: method is easy to implement; it requires no specific skills and special laboratory equipment, provides the scar-free corneal epithelium recovery over a relatively short period of time by stimulating proper regeneration.
SUBSTANCE: group of inventions refers to medical equipment and describes versions of a sprayer for subcutaneous liquid injection and a needle unit. According to the first version, the sprayer comprises a body, a needle unit and a rubber element. The body comprises a drive, a cam turned by the drive, and a connection element reciprocated by the cam. The needle unit is detachably connected to the front end of the body. The rubber element is provided in the needle unit to block a leak-off of blood and liquid from a patient's skin flowing into the needle unit during a medical procedure. The needle unit comprises a needle holder, a liquid container, a movable rod and a lid. The needle unit of the sprayer for subcutaneous liquid injection, including a drug or a tattoo pigment applied on the skin, comprises a needle holder, a liquid container, a movable rod and a lid. The needle holder comprises needles and outlets for a liquid injection. The liquid container is connected to the needle holder via one hole and contains a liquid. One side of the movable rod is connected to the liquid container, and the other side thereof is detachably connected to one end of the drive in the above sprayer. The lid encloses the needle holder and the liquid container and comprises a support unit which the movable rod passes through. The group of inventions also involves a version of the sprayer and a version of the needle unit.
EFFECT: invention enables blocking a leak-off of the patient's blood and liquid flowing into the needle unit during a medical procedure.
16 cl, 9 dwg
SUBSTANCE: tattoo machine frame consists of a side wall made of one piece and an S-shaped fin. The side wall is adjacent to the S-shaped fin for at least 70% of its length. The S-shaped fin is made with a boss. The boss is made with a hollow groove. The clamp is made in the form of a flat bolt pin with an opening and a threaded stud and is mounted in the closed groove of the boss of the S-shaped fin with the ability to move in a direction perpendicular to the side wall. The threaded stud passes through the opening of the frame. The nut is mounted on a threaded stud at the side wall can have a thumbscrew shape. The frame can be made of aluminium alloy.
EFFECT: weight reduction of tattoo machine due to increasing the frame flexural rigidity and torsional rigidity, increasing the reliability of the holder due to more rigid structure of the clamp.
3 cl, 5 dwg
SUBSTANCE: group of inventions relates to medicine. Device contains supplying devices 1-4, memory device, made with possibility of storing parameters of active medication and/or ingredients of solutions of active medications and/or solution components. Selection device 10 is connected with memory device and is intended for selection of parameters of active medications and/or ingredients and/or components of solution. Computing device 11 is made with possibility of calculating additional parameters. Control computer 14 is made with possibility of controlling work of additional supplying device, made with possibility of supplying into organism of additional combined medical solution on the basis of calculated additional parameter. Described is method of supplying combined medical solution into patient's organism.
EFFECT: inventions ensure successive calculation of parameters of medical solution components and taking into account obtained values in the process of artificial feeding.
12 cl, 1 dwg
SUBSTANCE: invention refers to medical equipment, namely to devices for subcutaneous injections. The device comprises a body, a liquid container having an opened end and an applicator in the form of a drug cartridge having a first primary surface comprising a microneedle matrix, a liquid canal connecting the opened end of the container with the microneedle matrix, a first pressure accumulator and a second pressure accumulator. The applicator and the container are independently integrated in the body. The first pressure accumulator can apply a force to the applicator to project it in the direction substantially perpendicular to the first primary surface. The second pressure accumulator can automatically open the opened end of the container to form a liquid connection between the opened end of the container and the liquid canal, as well as to push the liquid through the opened end of the container, liquid canal and microneedle matrix. According to the second version of the device, the body comprises a common actuator functionally connected with the first and second pressure accumulators and actuating the first and second pressure accumulators. The first pressure accumulator comprises a spring with two bases covering the container from two sides, and a segment contacting the applicator. The spring is substantially U-shaped, and if unstressed, the spring is in a close proximity to the container, substantially in parallel with its longitudinal axis. The method involves the stages to provide the body comprising the drug cartridge with the opened end, the applicator having the first primary surface comprising the microneedle matrix, and the pressure accumulator used to apply a force to the applicator in the direction substantially perpendicular to the first primary surface. The pressure accumulator comprises the spring with two bases covering the container from two sides, and the segment contacting the applicator. The spring is substantially U-shaped, and if unstressed, the spring is in a close proximity to the container, substantially in parallel with its longitudinal axis. The microneedle matrix is automatically moved in the direction perpendicular to the first primary surface. The opened end of the cartridge is automatically opened. The fluid connection is formed between the opened end of the cartridge and the microneedle matrix. The fluid is automatically pushed out from the drug cartridge through the opened end of the cartridge into the microneedle matrix. According to the third version, the first pressure accumulator comprises the spring with two bases covering the container from two sides, and the segment contacting the applicator. The spring is substantially U-shaped, and if unstressed, the spring is in a close proximity to the container, substantially in parallel with its longitudinal axis. The presented devices can be actuated in one movement, thereby providing automatic and reliable patient's skin needling by the microneedle matrix and then automatic release and cutaneous introduction of the liquid placed into the ready-to-use drug cartridge in a controlled mode that provides the adequate digestion of this liquid.
EFFECT: effective delivery of a wide variety of the liquids meeting the user's demands and dosage individual for each specific patients can be achieved by the relatively injury-free method with a minimised probability of hollow microneedle displacement in skin penetration and the amount of the liquid remained in the device after introduction into the patient.
35 cl, 33 dwg
SUBSTANCE: as an ingredient of drinking water or beverage, water containing 1H16OD isotopologue in an amount from 0.0002 to 0.0278 molecular %. The invention provides higher individual's body resistance to the flight factors, such as: height gain, cabin and compartment noise increase, vibration, rolling, humidity disposal, time zone change.
EFFECT: higher resistance of the mammalian body to the effect of the flight factors on an aircraft.
2 tbl, 2 ex